US FDA approves Beximco Pharma’s Nadolol tablets

Beximco Pharmaceuticals Limited has received US Food and Drug Administration (FDA) approval for their Nadolol tablets (20mg, 40mg and 80mg), which are generic equivalent of Bristol-Myers Squibb’s Corgard tablets, for treating hypertension (high blood pressure) and angina pectoris (chest pain). 

Managing Director of Beximco Pharmaceuticals Nazmul Hassan MP on Sunday expressed his gratitude for the FDA approval.

This is Beximco Pharma’s fifth Abbreviated New Drug Application (ANDA) approved for the US market since the Company’s oral solid dosage facility was approved by the US FDA in June 2015.